EvidenceHealthScreeningCancer
Low-dose CT lung cancer screening in heavy smokers
- Study type:
- Large randomised controlled trials
- Topic:
- Cancer screening in high-risk populations
- Added:
- 2026-03-15
- Status:
- published
Strength of evidence
🟡 Moderate – Large randomised trials (NLST, NELSON) show disease-specific mortality reduction in heavy smokers, but small absolute benefit, no clear all-cause survival gain, and substantial harms.
Source
NLST (National Lung Screening Trial, USA) and NELSON (Netherlands-Belgium) randomized trials comparing low-dose CT screening versus chest X-ray or no screening in heavy current or former smokers.
Large randomised trials have tested **low‑dose CT (LDCT) screening** for lung cancer in heavy current or former smokers. The two key trials (NLST in the US and NELSON in Europe) compared: - invitation to periodic LDCT scans - versus chest X‑ray (NLST) or no screening (NELSON). Findings: - LDCT screening produced a **relative reduction in lung‑cancer‑specific mortality** (about 15–25% in high‑risk groups), - but the **absolute benefit** was small (roughly 3–5 fewer lung‑cancer deaths per 1 000 high‑risk people screened over about a decade), - and there was **no clear, consistent reduction in all‑cause mortality** across trials. Screening led to many **false positives**, additional scans, biopsies and surgery, plus substantial **overdiagnosis** (detection of slow‑growing cancers that might never have caused symptoms).
Key findings
- In NLST, LDCT reduced lung‑cancer mortality by about 20% relative compared with chest X‑ray. In absolute terms, this corresponded to roughly 3 fewer lung‑cancer deaths per 1 000 heavy smokers screened over about 6–7 years.
- In NELSON, LDCT screening reduced lung‑cancer mortality in men by about 24–26% relative after 10 years; absolute differences were again small, on the order of a few fewer lung‑cancer deaths per 1 000 screened.
- In NLST, there was a small relative reduction in all‑cause mortality (around 7%), but the absolute effect was tiny and sensitive to analytic choices.
- In NELSON and combined analyses, no clear, consistent reduction in all‑cause mortality emerged.
- LDCT identifies many small lung nodules, most of which are not cancer, leading to many false‑positive results.
- In NLST, a large proportion of participants had at least one false‑positive result, leading to additional CT scans, PET scans, bronchoscopies, needle biopsies, and some thoracic surgeries for lesions that turned out to be benign.
- NELSON reported substantial overdiagnosis, particularly early in follow‑up. With longer follow‑up, overdiagnosis estimates decreased but remained non‑trivial.
- Repeated LDCT scans expose participants to cumulative radiation, which may (in theory) increase cancer risk.
- Screening also uncovers many incidental findings (for example, other lung changes or coronary calcifications) that can trigger further medical investigations, with uncertain benefit and potential harm.
Background
- Lung cancer is one of the leading causes of cancer death. Most cases are diagnosed at a late stage, especially in long‑term smokers. Low‑dose CT (LDCT) screening aims to detect tumours earlier, when surgery may be curative. The central questions are: Does LDCT screening in heavy smokers reduce lung‑cancer‑specific mortality? Does it meaningfully reduce all‑cause mortality? What are the harms in terms of false positives, overdiagnosis, radiation exposure and invasive follow‑up procedures?
Methods
- The two most influential trials are: 1. NLST (National Lung Screening Trial, USA) – Over 53 000 current or former heavy smokers (generally 55–74 years, ≥30 pack‑years). Randomised to three annual LDCT scans versus three annual chest X‑rays. Follow‑up about 6–7 years initially, later extended. Outcomes: lung‑cancer incidence, lung‑cancer mortality, all‑cause mortality, false positives, invasive procedures. 2. NELSON (Netherlands and Belgium) – About 15 000 heavy smokers (men and a smaller female subgroup). Randomised to LDCT at increasing intervals (baseline, year 1, 3, 5.5) versus no screening. About 10 years of follow‑up. Outcomes similar to NLST, including detailed analysis of tumour stage, mortality and overdiagnosis. Both trials included only high‑risk smokers or ex‑smokers; people who had never smoked were not screened.
Results
- Lung‑cancer‑specific mortality: In NLST, LDCT reduced lung‑cancer mortality by about 20% relative compared with chest X‑ray. In absolute terms, this corresponded to roughly 3 fewer lung‑cancer deaths per 1 000 heavy smokers screened over about 6–7 years. In NELSON, LDCT screening reduced lung‑cancer mortality in men by about 24–26% relative after 10 years; absolute differences were again small, on the order of a few fewer lung‑cancer deaths per 1 000 screened. The female subgroup was smaller but suggested a similar or slightly larger relative effect. All‑cause mortality: In NLST, there was a small relative reduction in all‑cause mortality (around 7%), but the absolute effect was tiny and sensitive to analytic choices. In NELSON and combined analyses, no clear, consistent reduction in all‑cause mortality emerged. The overall number of deaths from any cause did not change markedly. Overdiagnosis and false positives: LDCT identifies many small lung nodules, most of which are not cancer. In NLST, a large proportion of participants had at least one false‑positive result, leading to additional CT scans, PET scans, bronchoscopies, needle biopsies, and some thoracic surgeries for lesions that turned out to be benign. NELSON reported substantial overdiagnosis, particularly early in follow‑up. With longer follow‑up, overdiagnosis estimates decreased but remained non‑trivial (a proportion of screen‑detected cancers would not have become clinically apparent during the person's lifetime). Radiation exposure and incidental findings: Repeated LDCT scans expose participants to cumulative radiation, which may (in theory) increase cancer risk, though this is hard to quantify. Screening also uncovers many incidental findings (for example, other lung changes or coronary calcifications) that can trigger further medical investigations, with uncertain benefit and potential harm.
Interpretation
- From a conventional lung‑cancer‑control perspective, LDCT screening is often promoted as a life‑saving tool for heavy smokers because it reduces lung‑cancer‑specific mortality. From the WorthDay perspective: The benefit is real but modest and limited to high‑risk smokers. The absolute reduction in lung‑cancer deaths is small (a few per 1 000 screened over a decade). There is no robust evidence of a meaningful reduction in all‑cause mortality. Harms—false positives, invasive follow‑up, overdiagnosis, radiation—are significant and often under‑reported. That means LDCT screening is not a simple "yes for everyone who can get it". It is a trade‑off under uncertainty: a small chance of avoiding lung‑cancer death at the price of many people being pulled into a diagnostic and therapeutic cascade that may never have been necessary. For WorthDay, S0045 therefore earns a moderate‑quality evidence rating: lung‑cancer mortality can be reduced in a specific high‑risk group, but the overall impact on life expectancy is limited and must be judged against substantial harm.
Limitations
- Trials only included heavy smokers or ex‑smokers; results cannot be extrapolated to never‑smokers.
- Screening intervals, follow‑up duration and protocols differ between trials, complicating pooled estimates.
- All‑cause mortality effects are small and imprecise; even modest biases could change conclusions.
- Overdiagnosis estimates remain uncertain and depend on follow‑up length and assumptions about tumour biology.
- Radiation risks and downstream harms from incidental findings are not fully quantified.
- Quality‑of‑life data (anxiety, stress from false positives, long‑term consequences of invasive procedures) are limited.
WorthDay perspective
- S0045 shows that even one of the "strongest" cancer screening programmes—LDCT for lung cancer in heavy smokers—offers only a small absolute benefit in disease‑specific mortality and no clear gain in overall survival, while exposing many participants to false alarms, invasive tests and overdiagnosis.
- For WorthDay, this supports a moderate evidence rating and argues against simplistic slogans like "If you ever smoked, you must get screened." Instead, high‑risk individuals should see absolute numbers and be supported in deciding whether this trade‑off fits their values.
- In the Health category, LDCT screening is another reminder that more detection is not automatically more health. WorthDay Elements can help users focus on high‑impact behaviours—quitting smoking, improving food quality, moving more—where the potential benefits are much larger and side‑effects are positive, rather than relying on scans to compensate for lifestyle damage.
Permalink: https://www.worth-day.com/science-compass/s0045-low-dose-ct-lung-cancer-screening-in-heavy-smokers
Related studies
- PSA-Based Prostate Cancer Screening: Small Disease-Specific Benefit, No Clear Survival GainS0041
- Mammography Screening for Breast Cancer: Mortality and OverdiagnosisS0040
- General Health Checks in Adults: No Clear Benefit on Morbidity or MortalityS0042
- Adjuvant Chemotherapy After Surgery for Colon Cancer (Stage III)S0037
Science meets practice